Regulation of platelet function by catecholamines in the cerebral vasculature of the rabbit

British Journal of Pharmacology

Volumn 127, Issue 7, 1999, Pages 1652-1656

  Emerson, Michael ^a   Paul, William ^a   Page, Clive P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adrenergic receptors; Dopamine; Dopaminergic receptors; Platelets; Thrombin

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE DERIVATIVE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; PHENTOLAMINE; PROPRANOLOL; THROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN BLOOD VESSEL; CONTROLLED STUDY; INTRACEREBRAL DRUG ADMINISTRATION; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE FUNCTION;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PLATELETS; BLOOD VESSELS; CATECHOLAMINES; CEREBROVASCULAR CIRCULATION; DOPAMINE; DOPAMINE ANTAGONISTS; EPINEPHRINE; INDICATORS AND REAGENTS; INDIUM RADIOISOTOPES; MALE; RABBITS;

EID: 0032812949     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702671     Document Type: Article

References (28)

1. AHTEE, L. & MICHAL, F. (1972). Effects of sympathomimetic amines on rabbit platelet aggregation in vitro. Br. J. Pharmacol., 44, 363-364.
2. BOLLI, R., BRANDON, T.A., MACE, M.L. & WEILBACHER, D.G. (1985). Influence of χ-adrenergic blockade on platelet-mediated thrombosis in stenosed canine coronary arteries. Cardiovasc. Res., 19, 146-154.
3. BRAUNSTEIN, K.M., SARJI, K.E., KLEINFELDER, J., SCHRAIBMAN, H.B., COUWELL, J.A. & EURENIUS, K. (1977). The effects of dopamine on human platelet aggregation in vitro. J. Pharmacol. Expt. Ther., 200, 449-457.
4. DEAN, B., MCADAM, A.J., SUNDRAM, S., PAVEY, G., HARRISON, L.C. & COPOLOV, D.L. (1992). Identification of a dopamine-binding protein on the membrane of the human platelet. Biochem. J., 287, 45-50.
5. DE KEYSER, J., DEWAELA, M., CONVENTS, A., EBINGER, G. & VAUQUELIN, G. (1988). Identification of D1-like dopamine receptors on human blood platelets. Life Sciences, 42, 1797-1806.
6. ELLIOTT, W.J., WEBER, R.R., NELSON, K.S., OLINER, C.M., FUMO, N.T. GRETLER, D.D., MCGRAY, G.R. & MURPHY, M.B. (1990). Renal and haemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation, 81, 970-977.
7. EMERSON, M., GRESELE, P., PAGE, C.P. & PAUL, W. (1996). Antithrombotic activity of nitric oxide in the pulmonary vasculature of the rabbit. Br. J. Haematol., 93 (suppl. 2), 188. Abstract.
8. EMERSON, M., PAUL, W., FERLENGA, P., SEMERARO, C. & PAGE, C. (1997). Effects of dopamine and selective dopamine agonists upon platelet accumulation in the cerebral and pulmonary vasculature of the rabbit. Br. J. Pharmacol., 122, 682-686.
9. FEENSTRA, J., IN'T VELD, B.A., VAN DER LINDEN, P.D., GROBBEE, D.E. & STRICKER, B.H.CH. (1998). Risk factors for mortality in users of ibopamine. Br. J. Clin. Pharmacol., 46, 71-77.
10. FREDERICKSON, E.D., BRADLEY, T. & GOLDBERG, L.I. (1985). Blockade of renal effects of dopamine in the dog with the dopamine 1 antagonist SCH 23390. Am. J. Physiol., 249, F236-F240.
11. GOLDBERG, L.I. (1972). Cardiovascular and renal actions of dopamine: Potential clinical applictions. Pharmacol. Rev., 24, 1-29.
12. 2-adrenoceptors primarily responsible for inducing platelet aggregation. Nature, 277, 659-661.
13. HAMPTON, J.R., VAN VELDHUISEN, D., KLEBER, F.X., COWLEY, A.J., ARDIA, A., BLOCK, P., CORTINA, A., CSERHALMI, L., FOLLATH, F., JENSEN, G., KAYANAKIS, J., LIE, K.I., MANCIA, G. & SKENE, A.M. (1997). Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet, 349, 971-977.
14. HUGHES, A., THOM, S., MARTIN, G., REDMAN, D., HASAN, S. & SEVER, P. (1986). The action of dopamine (DA1) receptor agonist fenoldopam in human vasculature in vivo and in vitro. Br. J. Clin. Pharmacol., 22, 535-540.
15. KERRY, R. & SCRUTTON, M.C. (1983). Platelet β-adrenoceptors. Br. J. Pharmacol., 79, 681-691.
16. 2-adrenergic receptors on intact and functional washed human platelets by binding of 3H-dihydroergocryptine and 3H-yohimbine-correlation of 3H-yohimbine binding with the potentiation by adrenaline of ADP-induced aggregation. Thromb. Haemost., 54, 402-408.
17. LORENZ, R., PASCHKE, C., BORN, P. & CLEMENS, R. (1995). In vitro effects of the selective dopamine 1-agonist fenoldopam on the coagulation system in native whole blood: Comparison to dopamine and nitroprusside. Thromb. Res., 77, 113-118.
18. MAY, G.R., HERD, C.M., BUTLER, K.D. & PAGE, C.P. (1990). Radioisotopic model for investigating thromboembolism in the rabbit. J. Pharmacol. Meth., 24, 19-35.
19. MILLS, D.C.B. & ROBERTS, G.C.K. (1967). Effects of adrenaline on human blood platelets. J. Physiol., 193, 443-453.
20. MORLEY, J. & PAGE, C.P. (1984). Platelet aggregometry in vivo. Trends Pharmacol Sci., 5, 258-260.
21. O'BRIEN, J.R. (1963). Some effects of adrenaline and anti-adrenaline compounds on platelets in vitro and in vivo. Nature, 200, 763-764.
22. OYEKAN, A.O. & BOTTING, J.H. (1986). A minimally invasive technique for the study of intravascular platelet aggregation in anaesthetized rats. J. Pharmacol. Meth., 15, 271-277.
23. PACKHAM, M.A., GUCCIONE, M.A., CHANG, P.L. & MUSTARD, J.F. (1973). Platelet aggregation and release: effect of low concentrations of thrombin or collagen. Am. J. Physiol., 225, 38-47.
24. ROIZEN, M.F., WEISE, V., MOSS, J. & KOPIN, I.J. (1975). Plasma catecholamines: arterial-venous difference and the influence of body temperature. Life Sci., 16, 1133-1143.
25. SHATTIL, S.J., BUDZYNSKI, A. & SCRUTTON, M.C. (1989). Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding and aggregation of platelets in whole blood in the absence of other excitatory agonists. Blood, 73, 150-158.
26. SHUSTERMAN, N.H., ELLIOT, W.J. & WHITE, W.B. (1993), Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am. J. Med., 95, 161-168.
27. 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Thromb. Haemost., 70, 506-513.
28. TARAZI, R.C. (1974). Sympathomimetic agents in the treatment of shock. Ann. Intern. Med., 81, 364-371.